Program Overview
This CME program will highlight treatment strategies for basal insulins to manage time-in-range and glucose variability to improve outcomes in patients with diabetes. The expert faculty, Dr. Neil S. Skolnik, will outline the importance of improving patients’ glucose to time-in-range, minimize glucose variability, and incorporate continuous glucose monitoring in patients with diabetes. Following, Dr. Skolnik will discuss how to distinguish between insulins and how to incorporate them into practice. To conclude, he will review how to tailor treatment plans with the interprofessional team and the activated patient with diabetes, thus improving patient outcomes.
Target Audience
General practitioners, diabetes educators, nurses, pharmacists, and others interested in the management of patients with diabetes
Agenda
I. The Importance of Maximizing Patients’ Glucose in Time-in-Range, Minimize Glucose Variability, and Incorporate Continuous Glucose Monitoring in Patients with Diabetes
II. Scientific Update on Longer-acting Insulins and Their Role in Managing Patients with Diabetes
III. Clinical Strategies for Individualized Treatment Plans that Coordinate the Interprofessional Team and Inform the Patients on the importance of Minimizing Glucose Variability
Learning Objectives
- Recognize the importance of improving patients’ glucose to time-in-range, minimizing glucose variability, and incorporating continuous glucose monitoring in patients with diabetes
- Distinguish between insulins and incorporate them into practice in patients with diabetes
- Tailor treatment plans with the interprofessional team and the activated patient with diabetes
Faculty
Neil S. Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Abington Jefferson Health
Jenkintown, PA
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Neil S. Skolnik, MD | Consultant/Advisor: Abbot; AstraZeneca; Bayer AG; Boehringer Ingelheim International GmbH; Genentech, Inc.; GlaxoSmithKline plc; Idorsia Pharmaceuticals, Ltd.; Lilly; Pasteur Pharmacy; Sanofi US; Teva Pharmaceutical Industries Ltd.
Grant/Research Support: AstraZeneca; Bayer AG; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Sanofi US Speaker’s Bureau: AstraZeneca; Bayer AG; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Lilly; Novo Nordisk A/S |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council forPharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM.
Clinicians should only claim credit commensurate with the extent of their participation.
Financial Support
This activity has been supported by independent educational grant Sanofi US.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi US do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 50% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
